OptimizeRx Corp. reported that its year-to-date results for the second quarter of 2025 continued to deliver profitable growth, exceeding expectations. Contracted revenue is now up more than 30% year-over-year, positioning the company for a strong second half.
Based on this sustained performance, OptimizeRx increased its full-year 2025 guidance for the second time this year. The company now expects revenue to be between $104 million and $108 million, and Adjusted EBITDA to be between $14.5 million and $17.5 million.
The company also announced that it paid down $4.5 million of principal on its outstanding term loan during the second quarter, which was $4.0 million above its scheduled debt payment. OptimizeRx intends to continue paying down its debt at an accelerated rate, driven by strong free cash flow generation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.